University of Münster

About: University of Münster is a education organization based out in Münster, Germany. It is known for research contribution in the topics: Population & Catalysis. The organization has 35609 authors who have published 69059 publications receiving 2278534 citations. The organization is also known as: University of Munster & University of Muenster.

The Word Frequency Effect A Review of Recent Developments and Implications for the Choice of Frequency Estimates in German

Abstract: We review recent evidence indicating that researchers in experimental psychology may have used suboptimal estimates of word frequency. Word frequency measures should be based on a corpus of at least 20 million words that contains language participants in psychology experiments are likely to have been exposed to. In addition, the quality of word frequency measures should be ascertained by correlating them with behavioral word processing data. When we apply these criteria to the word frequency measures available for the German language, we find that the commonly used Celex frequencies are the least powerful to predict lexical decision times. Better results are obtained with the Leipzig frequencies, the dlexDB frequencies, and the Google Books 2000-2009 frequencies. However, as in other languages the best performance is observed with subtitle-based word frequencies. The SUBTLEX-DE word frequencies collected for the present ms are made available in easy-to-use files and are free for educational purposes.

S100A9/S100A8: Myeloid representatives of the S100 protein family as prominent players in innate immunity.

Abstract: Neutrophils are rapidly recruited to sites of inflammation and are thereby at the forefront of the organism's defense against numerous attacks As unspecific phagocytes, they belong to the so-called innate immunity Two S100 proteins, namely S100A9 (MRP14) and S100A8 (MRP8), constitute roughly 40% of the cytosolic protein in these cells, implying by their pure abundance an important role in the effector functions of neutrophils However, despite intense research in the past 15 years, the puzzle that may embed both molecules into the neutrophil/monocyte physiology is still incomplete One reason might be the conformational variability the S100A9 and S100A8 molecules can adopt They readily form hetero- and homodimeric, trimeric as well as tetrameric complexes, but they evidently do also exert specific functions as monomers An ever-increasing body of information suggests that S100A9 plays a prominent role in leukocyte trafficking and arachidonic acid metabolism In addition, elevated levels of S100A9 and S100A8 in body fluids of inflamed tissues strengthen the view that these molecules are important players in fighting inflammation The aim of this review is to give an update on the current developments concerning the S100A9/S100A8 molecule in biology and medicine

Systemic therapy in metastatic renal cell carcinoma

Abstract: Current systemic treatment of targeted therapies, namely the vascular endothelial growth factor-antibody (VEGF-AB), VEGF receptor tyrosine kinase inhibitor (TKI) and mammalian target of rapamycin (mTOR) inhibitors, have improved progression-free survival and replaced non-specific immunotherapy with cytokines in metastatic renal cell carcinoma (mRCC). A panel of experts convened to review currently available phase 3 data for mRCC treatment of approved agents, in addition to available EAU guideline data for a collaborative review as the plurality of substances offers different options of first-, second- and third-line treatment with potential sequencing. Sunitinib and pazopanib are approved treatments in first-line therapy for patients with favorable- or intermediate-risk clear cell RCC (ccRCC). Temsirolimus has proven benefit over interferon-alfa (IFN-α) in patients with non-clear cell RCC (non-ccRCC). In the second-line treatment TKIs or mTOR inhibitors are treatment choices. Therapy options after TKI failure consist of everolimus and axitinib. Available third-line options consist of everolimus and sorafenib. Recently, nivolumab, a programmed death-1 (PD1) checkpoint inhibitor, improved overall survival benefit compared to everolimus after failure of one or two VEGFR-targeted therapies, which is likely to become the first established checkpoint inhibitor in mRCC. Data for the sequencing of agents remain limited. Despite the high level of evidence for first and second-line treatment in mRCC, data for third-line therapy are limited. Possible sequences include TKI-mTOR-TKI or TKI–TKI-mTOR with the upcoming checkpoint inhibitors in perspective, which might settle a new standard of care after previous TKI therapy.